Literature DB >> 27857974

Antiangiogenic resistance via metabolic symbiosis.

Gabriela Jiménez-Valerio1, Oriol Casanovas1.   

Abstract

Several types of tumor are currently treated with antiangiogenic drugs. Unfortunately, most of these patients develop therapy resistance and succumb to the disease. Recently, a novel mechanism of resistance to antiangiogenics involving metabolic symbiosis of tumor cells has been described. Strategies to block resistance are emerging as a promising therapeutic approach.

Entities:  

Keywords:  Angiogenesis; antiangiogenic resistance; antiangiogenic therapy; mTOR; metabolic symbiosis

Year:  2016        PMID： 27857974      PMCID： PMC5068180          DOI： 10.1080/23723556.2016.1211979

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  8 in total

1.  Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells.

Authors:  Peter B Makhov; Konstantin Golovine; Alexander Kutikov; Ervin Teper; Daniel J Canter; Jay Simhan; Robert G Uzzo; Vladimir M Kolenko
Journal:  Mol Cancer Ther       Date:  2012-04-24       Impact factor: 6.261

2.  Expression of lactate/H⁺ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and The Cancer Genome Atlas data analyses.

Authors:  Younghye Kim; Jung-Woo Choi; Ju-Han Lee; Young-Sik Kim
Journal:  Hum Pathol       Date:  2014-10-07       Impact factor: 3.466

3.  Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice.

Authors:  Pierre Sonveaux; Frédérique Végran; Thies Schroeder; Melanie C Wergin; Julien Verrax; Zahid N Rabbani; Christophe J De Saedeleer; Kelly M Kennedy; Caroline Diepart; Bénédicte F Jordan; Michael J Kelley; Bernard Gallez; Miriam L Wahl; Olivier Feron; Mark W Dewhirst
Journal:  J Clin Invest       Date:  2008-11-20       Impact factor: 14.808

4.  Cancer cell metabolism: Warburg and beyond.

Authors:  Peggy P Hsu; David M Sabatini
Journal:  Cell       Date:  2008-09-05       Impact factor: 41.582

5.  Comprehensive molecular characterization of clear cell renal cell carcinoma.

Authors: 
Journal:  Nature       Date:  2013-06-23       Impact factor: 49.962

6.  Targeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic Therapy.

Authors:  Laura Pisarsky; Ruben Bill; Ernesta Fagiani; Sarah Dimeloe; Ryan William Goosen; Jörg Hagmann; Christoph Hess; Gerhard Christofori
Journal:  Cell Rep       Date:  2016-04-28       Impact factor: 9.423

7.  Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling.

Authors:  Elizabeth Allen; Pascal Miéville; Carmen M Warren; Sadegh Saghafinia; Leanne Li; Mei-Wen Peng; Douglas Hanahan
Journal:  Cell Rep       Date:  2016-04-28       Impact factor: 9.423

8.  Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients.

Authors:  Gabriela Jiménez-Valerio; Mar Martínez-Lozano; Nicklas Bassani; August Vidal; María Ochoa-de-Olza; Cristina Suárez; Xavier García-Del-Muro; Joan Carles; Francesc Viñals; Mariona Graupera; Stefano Indraccolo; Oriol Casanovas
Journal:  Cell Rep       Date:  2016-04-28       Impact factor: 9.423
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.